Cantor Fitzgerald Estimates Zai Lab FY2025 Earnings

Zai Lab Limited (NASDAQ:ZLAB - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Zai Lab in a report issued on Tuesday, March 4th. Cantor Fitzgerald analyst L. Watsek forecasts that the company will post earnings of ($1.38) per share for the year. Cantor Fitzgerald currently has a "Strong-Buy" rating on the stock. The consensus estimate for Zai Lab's current full-year earnings is ($2.58) per share.

Several other research analysts have also recently weighed in on ZLAB. Scotiabank assumed coverage on Zai Lab in a research report on Friday. They set a "sector outperform" rating and a $55.00 price objective for the company. Bank of America reaffirmed a "neutral" rating and set a $36.10 price target (up previously from $29.00) on shares of Zai Lab in a research report on Monday, March 3rd.

Zai Lab Price Performance

ZLAB stock traded down $1.73 during trading hours on Thursday, reaching $34.69. 862,424 shares of the stock were exchanged, compared to its average volume of 751,476. The firm's 50-day moving average is $28.46 and its 200-day moving average is $26.58. Zai Lab has a 12 month low of $13.48 and a 12 month high of $37.99. The company has a market cap of $3.80 billion, a price-to-earnings ratio of -12.52 and a beta of 1.08.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.19). The company had revenue of $109.07 million for the quarter, compared to the consensus estimate of $110.15 million. Zai Lab had a negative return on equity of 36.97% and a negative net margin of 76.14%.

Remove Ads

Institutional Investors Weigh In On Zai Lab

Several hedge funds have recently bought and sold shares of ZLAB. Janus Henderson Group PLC increased its position in Zai Lab by 34.2% during the third quarter. Janus Henderson Group PLC now owns 8,760,074 shares of the company's stock worth $211,488,000 after buying an additional 2,232,507 shares during the last quarter. Wellington Management Group LLP raised its stake in Zai Lab by 18.4% in the 3rd quarter. Wellington Management Group LLP now owns 8,436,606 shares of the company's stock valued at $203,660,000 after acquiring an additional 1,312,115 shares during the period. FMR LLC raised its stake in Zai Lab by 749.1% in the 4th quarter. FMR LLC now owns 5,475,505 shares of the company's stock valued at $143,403,000 after acquiring an additional 4,830,646 shares during the period. RTW Investments LP acquired a new stake in Zai Lab during the 4th quarter valued at $65,714,000. Finally, Price T Rowe Associates Inc. MD boosted its position in Zai Lab by 30.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,354,025 shares of the company's stock worth $61,653,000 after purchasing an additional 548,378 shares during the period. 41.65% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Zai Lab news, insider Rafael Amado sold 7,583 shares of the company's stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $26.28, for a total transaction of $199,281.24. Following the sale, the insider now directly owns 33,834 shares of the company's stock, valued at approximately $889,157.52. This represents a 18.31 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Ying Du sold 50,000 shares of the stock in a transaction on Friday, February 28th. The shares were sold at an average price of $34.47, for a total transaction of $1,723,500.00. Following the completion of the sale, the chief executive officer now owns 494,117 shares of the company's stock, valued at approximately $17,032,212.99. This represents a 9.19 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 122,127 shares of company stock worth $4,024,442 in the last quarter. Corporate insiders own 13.88% of the company's stock.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.